Mirum Pharmaceuticals, Inc.
MIRM· Nasdaq
Released Aug 7, 2024, after the close
10-Q filed Aug 7, 2024, 38 days after period end · 0001759425-24-000031
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $77.88M | $37.50M | $17.48M | $11.00M |
| Net Income | -$24.64M | -$74.04M | -$26.92M | -$43.89M |
| EPS Diluted |
Mirum Pharmaceuticals, Inc. · CIK 1759425 · Engraved from SEC EDGAR
| -$0.52 |
| -$1.94 |
| -$0.84 |
| -$1.45 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.